Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects

All subjects: Inclusions Criteria: * Subjects must weight at least 50 kg, with a BMI within the range of 18 to 38 kg/m2 * Must be willing to remain in the clinical research unit as required by the protocol Exclusion Criteria: * Use of other study drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever is longer; or longer if required by local regulations * History of hypersensitivity to the study treatment or to drugs of similar chemical classes * Pregnant or nursing women * Women of child-bearing potential Healthy Volunteers: Inclusion Criteria: \- In good health as determined by past medical history, physical examination, ECG, laboratory tests, and urinalysis at Screening. Exclusion Criteria: * Liver disease or liver injury * Chronic infection with Hepatitis B or Hepatitis C * History or presence of impaired renal function Hepatically Impaired Subjects: Inclusion Criteria: \- Hepatic impairment as defined by the Child-Pugh classification for severity of liver disease Exclusion Criteria: * Severe complications of liver disease within the preceding 3 months * Emergency room visit or hospitalization due to liver disease within the preceding 3 months for mildly and moderately hepatically impaired subjects, and within the preceding 1 month for severely hepatically impaired subjects * Subject has received liver transplant at any time in the past and is on immunosuppressant therapy * Acute Hepatitis B or Hepatitis C infection Other protocol-defined inclusion/exclusion criteria may apply.